Exact Sciences

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exact Sciences excels in Q4, eyes international growth and innovation

Exact Sciences delivered a robust financial performance in Q4 2022, driven by revenue growth and advancements in precision oncology.
The company's focus on compliance improvements, international expansion, and new product development positions it for future success.
Challenges in profitability, domestic market growth, and product validation are being addressed through strategic investments and operational enhancements.
Opportunities in international markets, Medicare coverage expansion, and legislative advantages provide avenues for sustained growth and market leadership.

Exact Sciences reports record-breaking Q1 revenue and anticipates strong growth opportunities

Exact Sciences' Q1 performance reflects strong revenue growth and strategic advancements in product development. The company's focus on partnerships, innovation, and market expansion positions it well for sustained growth. With a positive outlook for the year and a clear strategic direction, Exact Sciences is poised for continued success.

Exact Sciences excels in Q2 earnings, eyes international expansion

Exact Sciences delivered robust financial performance in Q2 2023, driven by revenue growth and innovative test developments.
While facing challenges like seasonality and capacity issues, the company is well-positioned to capitalize on opportunities for expansion and market penetration.
Strategic partnerships, positive test feedback, and revenue guidance raise optimism for Exact Sciences' future growth trajectory.
Focus on efficiency, innovation, and international expansion underscores the company's commitment to long-term success and market leadership.

Exact Sciences excels in Q3, eyes growth through innovation and partnerships

Exact Sciences delivered strong Q3 results, showcasing robust revenue, EBITDA, and Cologuard milestones, while addressing analyst inquiries on market strategies and growth sustainability.
The company's strengths in product innovation, strategic partnerships, and financial prudence position it well for future expansion and market leadership.
Challenges in capacity constraints, market dynamics, and regulatory compliance require proactive management strategies to mitigate risks and drive sustainable growth.
Opportunities in market expansion, product development, and strategic initiatives offer avenues for Exact Sciences to capitalize on its strengths and navigate challenges effectively.

Exact Sciences reports record-breaking 2023 results and eyes international growth

Exact Sciences delivered exceptional results in 2023, with strong financial performance and strategic growth initiatives. The company's focus on innovation, partnerships, and market expansion positions it well for sustained success.
Challenges in reimbursement pathways and market dynamics require careful navigation and strategic planning. Opportunities in expanding market reach, leveraging technology, and advancing key programs offer avenues for future growth.
With a clear focus on precision oncology, international expansion, and enhancing screening effectiveness, Exact Sciences is poised for continued success. Strategic investments in growth areas and operational efficiencies demonstrate a commitment to long-term value creation.

Exact Sciences reports robust Q1 earnings, eyes growth opportunities

Exact Sciences' strong Q1 performance and strategic initiatives position the company for continued growth in cancer eradication efforts and revenue generation.
While facing challenges such as cash flow management and regulatory uncertainties, the company's focus on innovation and market penetration presents opportunities for future success.
With a positive outlook for the year ahead and a commitment to addressing market challenges, Exact Sciences remains poised for sustained growth and competitive advantage.

Exact Sciences excels in Q2 with record screening and revenue

Exact Sciences delivered impressive financial performance in Q2 2024, with record screening numbers and revenue growth.
Their focus on innovation and product launches indicates a commitment to advancing cancer screening technology.
While facing challenges in a competitive market, the company's strategic planning and confidence in future success position them well for growth.

Exact Sciences reports 13% revenue growth in Q3 2024

Exact Sciences delivered solid Q3 performance with revenue growth and margin expansion, despite facing challenges in Cologuard adoption and Precision Oncology transition.
The company is optimistic about growth prospects in 2025, focusing on key initiatives like Cologuard Plus launch and achieving higher EBITDA margins by 2027.
With a clear roadmap for addressing challenges and leveraging growth opportunities, Exact Sciences aims to drive sustainable revenue growth and profitability in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen

Gilead Sciences

GlaxoSmithKline

Immunocore Holdings

Eli Lilly

Moderna

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

The industry is home to some large-cap heavyweights, including Amgen Inc. (NASDAQ: AMGN), Gilead Sciences Inc. (NASDAQ: GILD), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and Moderna Inc. (NASDAQ: MRNA), among others.

Is Biotech Immunocore About To Make A 25% Price Move?

AbbVie

Align Technology

Baxter

BeiGene

Centene

GE HealthCare Technologies Inc

IDEXX Laboratories

Neurocrine Biosciences

Pfizer

After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022.

5 Best and Worst Performing Healthcare Stocks in January 2023

Exact Sciences' revenue has doubled in just a few years, and sales of its Cologuard test continue to soar.

Could Exact Sciences Stock Help You Become a Millionaire?

In November 2021, Cathie Wood described artificial intelligence as the “next big frontier” of the tech sector. Roughly a year later, OpenAI released advanced chatbot ChatGPT, and almost overnight, the ways investors viewed AI began to shift.

Cathie Wood Is Doubling Down on This Hidden-Gem Artificial Intelligence Stock

MADISON, Wis. , Feb. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2022 financial results after the close of the U.S. financial markets on February 21, 2023.

Exact Sciences schedules fourth quarter 2022 earnings call

Here is how Exact Sciences (EXAS) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

Has Exact Sciences (EXAS) Outpaced Other Medical Stocks This Year?

Veracyte

As cancer screenings are becoming covered more often, both companies stand to gain.

Better Long-Term Buy in 2023: Exact Sciences or Veracyte?

ARK Innovation ETF

Coinbase

Roku

Wood's ARK Innovation ETF is rebounding nicely.

Cathie Wood Is Trouncing the Market So Far in 2023 Mainly Due to These 3 Stocks

UiPath

Shopify

Block

Tesla

Zoom Video

The popular investment manager is attracted to innovative companies.

48.8% of Cathie Wood's Portfolio Is in These 7 Stocks

Investors are attracted to its leading position in the market for early cancer detection, but the persistent losses its been reporting are enough to make anyone nervous.

Down 40% in 2022, Can Exact Sciences Recover in 2023?

CRISPR Therapeutics

DraftKings

Invitae

Pacific Biosciences of California

Roblox

10X Genomics

Cathie Wood's ARK Innovation ETF is back — and back big. It's the top diversified ETF again this year so far, largely due to big winners.

Cathie Wood Is Crushing It This Year Thanks To 9 Stocks

Cathie Wood is known for her deep understanding of tech companies and for holding aggressive long positions in her tech funds. Let's look at what she's buying.

Cathie Wood Is Buying These Stocks, Should You?

American Airlines

JinkoSolar Holding

While inflation remains the market's primary concern, these three stocks have gotten off to a great start in 2023, already up more than 20% year-to-date. Can the strength continue?

3 Top Stocks Already up More Than 20% In 2023

The company's fast-growing business has loads of potential, but it may not be suitable for all investors.

Is Exact Sciences a Buy?

Despite its price surge, EXAS's valuation remains aligned with industry averages. EXAS has one of the clearest profitability paths in a market characterized by heavy losses stemming from aggressive growth initiatives.

Exact Sciences Up 25% YTD: Here Is What To Expect In 2023

Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.

Here's Why Investors Should Buy Exact Sciences (EXAS) Stock

Shares of Exact Sciences, Inc. EXAS have been on a tear, having gained over 27% in two sessions this week.

Cathie Wood Makes This Molecular Diagnostics Company Top Holding Of Ark Invest's Flagship Fund, Catapulting Past Zoom, Tesla

Exact Science's stock price is shooting higher this week amid posting upward revisions for its revenue and earnings estimates for this quarter.

Exact Sciences Corp Stock Price Is Trending Up Here's Why

As we head into a new year, investors are taking a look at their portfolios to determine which stocks were winners and losers in 2022.

Cathie Wood's Top 5 Stocks See Abysmal Year in 2022

Exact Sciences (EXAS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Exact Sciences (EXAS): Can Its 24.7% Jump Turn into More Strength?

Exact Sciences Corp EXAS gapped up more than 16% to start the trading day on Monday and continued to surge an additional 5.6% before hitting and rejecting a resistance area near $58.50.

Exact Sciences Breaks Up From This Pattern, Signals Massive Reversal: Is A Bull Cycle In The Cards? - Exact Sciences (NASDAQ:EXAS)

EXAS stock jumped as the provider of cancer screening and diagnostic tests raised estimates for its fourth quarter. The post Exact Sciences Raises Fourth-Quarter Estimates Above Expectations appeared first on Investor's Business Daily.

Exact Sciences Raises Fourth-Quarter Estimates Above Expectations

A revenue increase of 28% in the December quarter helps deliver profits ahead of schedule.

Cologuard Maker Exact Sciences Reports Big Sales and a Surprise Profit

Exact Sciences Corp EXAS shares are trading higher Monday after the company announced preliminary fourth-quarter results.

What's Going On With Exact Sciences Stock? - Exact Sciences (NASDAQ:EXAS)

ARK Invest's Cathie Wood believes Exact Sciences (EXAS) can hit $140 per share by 2027. Unlike some other calls, I believe Cathie and ARK are spot-on with EXAS. EXAS is a major holding in both Cathie's ARK Innovation ETF (ARKK) and ARK Genomic Revolution ETF (ARKG). Together, it looks as if they make up about 10% of EXAS.

News for Exact Sciences Stock (EXAS)